PTC Therapeutics (NASDAQ:PTCT) Upgraded at UBS Group

Posted by George Bondi on Oct 17th, 2026

UBS Group upgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) to a strong-buy rating in a research report report published on Wednesday morning,Zacks reports.

Other equities analysts have also issued research reports about the company. Zacks Research lowered PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings raised shares of PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Cantor Fitzgerald increased their price target on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an “overweight” rating in a research report on Tuesday, September 22nd. Wells Fargo & Company raised their price target on shares of PTC Therapeutics from $106.00 to $109.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Finally, Royal Bank Of Canada cut their price objective on shares of PTC Therapeutics from $85.00 to $75.00 and set a “sector perform” rating on the stock in a research report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.07.

Check Out Our Latest Report on PTC Therapeutics

PTC Therapeutics Trading Down 2.9%

Shares of NASDAQ:PTCT traded down $1.75 on Wednesday, reaching $59.24. The company had a trading volume of 788,962 shares, compared to its average volume of 1,319,208. PTC Therapeutics has a 52-week low of $58.80 and a 52-week high of $90.87. The firm’s 50 day simple moving average is $67.41 and its 200-day simple moving average is $71.73. The firm has a market capitalization of $4.94 billion, a PE ratio of -102.14, a PEG ratio of 1.84 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.24 by $0.68. The company had revenue of $360.52 million during the quarter, compared to the consensus estimate of $298.63 million. The company’s revenue was up 101.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.83) earnings per share. As a group, equities research analysts predict that PTC Therapeutics will post 1.19 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Mark Boulding sold 2,813 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $72.57, for a total transaction of $204,139.41. Following the completion of the sale, the vice president owned 105,272 shares in the company, valued at approximately $7,639,589.04. This represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Klein sold 10,292 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $68.57, for a total value of $705,722.44. Following the sale, the chief executive officer owned 383,868 shares of the company’s stock, valued at approximately $26,321,828.76. This represents a 2.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 77,370 shares of company stock valued at $5,322,261. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its holdings in shares of PTC Therapeutics by 16.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 151 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in PTC Therapeutics by 1.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,730 shares of the biopharmaceutical company’s stock worth $1,120,000 after acquiring an additional 237 shares during the period. PNC Financial Services Group Inc. grew its holdings in PTC Therapeutics by 8.5% during the first quarter. PNC Financial Services Group Inc. now owns 3,128 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 244 shares during the period. Evolve Private Wealth LLC grew its holdings in PTC Therapeutics by 5.2% during the first quarter. Evolve Private Wealth LLC now owns 6,122 shares of the biopharmaceutical company’s stock worth $417,000 after acquiring an additional 305 shares during the period. Finally, New York State Teachers Retirement System raised its position in PTC Therapeutics by 0.7% during the first quarter. New York State Teachers Retirement System now owns 44,953 shares of the biopharmaceutical company’s stock valued at $3,063,000 after acquiring an additional 316 shares in the last quarter.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs use technologies designed to address genetic and molecular causes of disease, including RNA biology, protein translation and gene therapy.

The company’s commercial portfolio includes Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency in eligible patients.